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Maintenance of musculoskeletal function and fall prevention
are important public health targets in a rapidly aging population
(1). Sarkopenia is prevalent in older persons and resulting in
falls among 30% percent of those 65 years or older, and 40-
50% of those 80 years or older (2, 3). 
Several beneficial effect of vitamin D have been described, the
most established one being improved bone mineral density
and fracture prevention (4-6). On the other hand, muscle weak-
ness is also a prominent feature of the clinical syndrome of vit-
amin D deficiency (7, 8) and may plausibly mediate fracture
risk through an increased susceptibility to falls (7, 9-13). In fact,
vitamin D appears to directly improve muscle strength (14, 15)
and effects on muscle strength occur within 8-12 weeks (10,
11, 16). 
A possible explanation for the beneficial effect of vitamin D on
fall risk is that 1,25-dihydroxyvitamin D, the active vitamin D
metabolite, binds to a highly specific nuclear receptor in mus-
cle tissue (17, 18) leading to improved muscle strength and
thus to a reduced risk of falling. It is currently believed that,
apart from rapid genome-independent calcium fluxes, 1,25-di-
hydroxyvitamin D elicits its biological response through the ac-
tivation of the vitamin D receptor (VDR), which leads to de no-
vo protein synthesis, affecting muscle cell growth (7, 11). 
In one study, which illustrates this hypothesis, treatment with 1-
alpha-hydroxyvitamin D increased the relative number and size
of type II muscle fibers of elderly women within three months of
treatment (11). Furthermore, two RCTs included in the meta-
analysis above found a positive effect of vitamin D on body
sway (16) and musculoskeletal function (10) in addition to the
documented reduction in falls, supporting that fall prevention
with vitamin D is likely to be mediated by improved muscu-
loskeletal function. Pfeifer and colleagues found a 9% de-
crease in body sway following a two-month treatment with vita-
min D (800 IU per day) plus calcium (1200 mg per day) com-
pared to calcium alone (1200 mg per day) (16). Similarly,
Bischoff and colleagues documented a 5-11% improvement in
grip strength, knee extensor and flexor strength, and the timed
up&go test following a three-month treatment with vitamin D
(800 IU per day) plus calcium (1200 mg per day) compared to
calcium alone (1200 mg per day) (10).
One meta-analysis addressed the effect of vitamin D on the
risk of falling in older persons (19). Based on 5 RCTs (n =
1237), vitamin D reduced the risk of falling by 22% (pooled cor-
rected OR = 0.78; 95% CI [0.64, 0.92]) compared to calcium or
placebo (10, 16, 20-22). Subgroup analyses suggested that the
reduction in risk was independent of the type of vitamin D, du-
ration of therapy, and gender. However, the results from one
trial suggested that 400 IU of vitamin D may not be clinically ef-
fective in preventing falls in the elderly (22), while two trials that
used 800 IU of vitamin D per day plus calcium reduced the risk
of falling (10, 16). For the two trials with 259 subjects using 800
IU of cholecalciferol, the corrected pooled OR was 0.65 (95%
CI [0.40, 1.00]) (19). A recent double-blind RCT testing the
long-term effect of 700 IU vitamin D plus 500 mg calcium com-
pared to placebo confirmed a benefit on falls among communi-
ty-dwelling older women (n = 246) with a 46% reduction in the
odds of falling (odds ratio [OR], 0.54; 95% confidence interval
[CI], 0.30-0.97) (23). Fall reduction was most pronounced in
less active women (OR, 0.35; 95% CI, 0.15-0.81), while the ef-
fect in community-dwelling older men was neutral (OR, 0.93;
95% CI, 0.50-1.72, n = 199). The neutral effect in men maybe
explained by higher physical activity and higher 25-hydroxyvit-
amin D [25(OH)D] levels among men in this trial compared to
women. Furthermore, the data suggested a possible benefit of
vitamin D on the risk of falling among less active men.
A threshold for optimal 25(OH)D and lower extremity function
has been addressed recently (15) examining the association
between serum 25(OH)D levels and lower-extremity function in
NHANES III including 4100 ambulatory older adults (15). Func-
tional assessment included the 8-foot-walk test and sit-to-stand
test (24, 25). Both tests depend on lower extremity strength,
and mirror functions needed in everyday life. For the 8-foot
walk test, compared to the lowest quintile of 25(OH)D, the
highest quintile showed an average decrease by 5.6% (test for
trend: p < 0.001). For the sit-to-stand test, compared to the
lowest quintile of 25(OH)D the highest quintile showed an aver-
age decrease by 3.9% (test for trend: p = 0.017).
In the regression plots of the NHANES III analysis, perfor-
mance speed continued to increase throughout the reference
range of 25(OH)D (22.5 to 94 nmol/l) with most of the improve-
ment occurring in 25(OH)D levels going from 22.5 to approxi-
mately 40 nmol/l (15). Further improvement was seen in the
range of 40-94 nmol. These results were similar for subgroups
of active and inactive individuals, men and women, three eth-
nic groups (Caucasians, African Americans and Mexican
Americans), and persons with higher (> 500 mg/day) and lower
calcium intakes ( 500 mg/day). 
Thus, for all subgroups of ambulatory older individuals the data
for lower extremity strength suggested that serum 25(OH)D
levels of at least 40 nmol/l are desirable, but 75-100 nmol/l are
best. This is supported by data published in abstract from the
Longitudinal Aging Study Amsterdam including 1351 Dutch
men and women aged 65 and older. In that study, a physical
performance score (chair stands, a walking test, and a tandem
stand) improved most from very low levels of serum 25(OH)D
up to 50 nmol/l, and less pronounced but continuously beyond
50 nmol/l (26). 
The optimal target of 75 nmol/l 25(OH)D for lower extremity
function is supported by threshold assessment for bone miner-
al density in younger and older adults (6), fracture efficacy in
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older adults (27), as well as a recent expert consensus for opti-
mal bone health (28). The minimal dose of vitamin D to
achieve both fall (19) and fracture prevention (27) has been
identified as 700-800 IU vitamin D per day (cholecalciferol).
In summary, it has become a public health priority to raise the
consciousness of the community towards ensuring sufficient vi-
tamin D status for both fall and fracture prevention, as well as
maintenance of muscle strength and lower extremity function.
Fall and fracture benefits have been observed with intakes of
at least 700-800 IU vitamin D (cholecalciferol) per day and a
target level for optimal lower extremity strength and bone
health has been suggested to be 75 nmol/l (30 ng/ml) 25(OH)D. 
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